Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase

References

• WardEDesantisCRobbinsAKohlerBJemalAChildhood and adolescent cancer statistics, 2014CA Cancer J Clin20146428310324488779
   PubMed Web of Science ®Google Scholar
• ChristensenMSHeymanMMöttönenMTreatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992–2001Br J Haematol20051311505816173962
   PubMed Web of Science ®Google Scholar
• BedrnaJPolcákJAkuter harnleiterverschluss nach bestrahlung chronischer leukämien mit röntgenstrahlenMed Klin19292517001701
   Google Scholar
• CrittendenDRAckermanGLHyperuricemic acute renal failure in disseminated carcinomaArch Intern Med197713719799831657
   PubMedGoogle Scholar
• CoiffierBAltmanAPuiC-HYounesACairoMSGuidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based reviewJ Clin Oncol200826162767277818509186
   PubMed Web of Science ®Google Scholar
• HandeKRGarrowGCAcute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphomaAm J Med19939421331398430709
   PubMed Web of Science ®Google Scholar
• KedarAGrowWNeibergerREClinical versus laboratory tumor lysis syndrome in children with acute leukemiaPediatr Hematol Oncol19951221291347626380
   PubMed Web of Science ®Google Scholar
• MontesinosPLorenzoIMartínGTumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive modelHaematologica2008931677418166787
   PubMed Web of Science ®Google Scholar
• AnnemansLMoeremansKLamotteMIncidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin’s lymphoma in four European countriesLeuk Lymphoma2003441778312691145
   PubMed Web of Science ®Google Scholar
• ArseneauJCCanellosGPBanksPMBerardCWGralnickHRDeVitaVTJrAmerican Burkitt’s lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survivalAm J Med19755833143211115074
   PubMed Web of Science ®Google Scholar
• OkamotoKKinoshitaTShimizuMA case of spontaneous tumor lysis syndrome in a patient with ovarian cancerCase Rep Obstet Gynecol2015201546187026161277
   PubMedGoogle Scholar
• BrintonTYousufTSteineckerGRydelJA case of tumor lysis syndrome in a patient with pancreatic adenocarcinoma treated with low-dose gemcitabineOchsner J201515445545626730234
   PubMedGoogle Scholar
• SalehRRRodriguesJLeeTCA tumour lysis syndrome in a chemotherapy naive patient with metastatic pancreatic adenocarcinomaBMJ Case Rep20152015
   Google Scholar
• LobeTEKarkeraMSCusterMDShenefeltREDouglassECFatal refractory hyperkalemia due to tumor lysis during primary resection for hepatoblastomaJ Pediatr Surg19902522492502154576
   PubMed Web of Science ®Google Scholar
• KushnerBHLaQuagliaMPModakSCheungN-KVTumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplificationMed Pediatr Oncol2003411808212764755
   PubMedGoogle Scholar
• AscaniSWentPLiberatiAMPiccalugaPPZinzaniPLPileriSADifficult diagnostic and therapeutic cases: Case 1. True thymic hyperplasia in a patient treated for T-cell lymphomaJ Clin Oncol200422595395414990652
   PubMedGoogle Scholar
• MirrakhimovAEAliAMKhanMBarbaryanATumor lysis syndrome in solid tumors: an up to date review of the literatureRare Tumors201462538925002953
   PubMedGoogle Scholar
• KaurVSwamiAIbrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: a case reportJ Oncol Pharm Pract Epub3112016
   Google Scholar
• KaurVMehtaPJohnsurdJGovindarajanRIbrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemiaBlood2014124233503350525431479
   PubMed Web of Science ®Google Scholar
• TamCSSeymourJFRobertsAWProgress in BCL2 inhibition for patients with chronic lymphocytic leukemiaSemin Oncol201643227427927040706
   PubMed Web of Science ®Google Scholar
• HowardSCTrifilioSGregoryTKBaxterNMcBrideATumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic reviewAnn Hematol20169556357326758269
   PubMed Web of Science ®Google Scholar
• AlkanAKütükTKarcıEYaşarAHiçsönmezAUtkanGRadiation induced tumor lysis syndrome in chronic lymphocytic leukemiaTurk J Haematol201633324825027093891
   PubMedGoogle Scholar
• ChenS-WHwangW-STsaoC-JLiuH-SHuangG-CHydroxyurea and splenic irradiation-induced tumour lysis syndrome: a case report and review of the literatureJ Clin Pharm Ther200530662362516336296
   PubMed Web of Science ®Google Scholar
• Abou MouradYTaherAShamseddineAAcute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20Hematol J20034322222412764356
   PubMedGoogle Scholar
• YunSVinceletteNDPhanTAnwerFSpontaneous tumour lysis syndrome associated with contrast dye iohexol use in mantle cell lymphomaBMJ Case Rep20142014
   Google Scholar
• WeeksACKimpleMESpontaneous tumor lysis syndrome: a case report and critical evaluation of current diagnostic criteria and optimal treatment regimensJ Investig Med High Impact Case Rep201533 2324709615603199
   Google Scholar
• SalsamendiJTDoshiMHGortesFJLeviJUNarayananGAcute tumor lysis syndrome after proximal splenic artery embolizationRadiol Case Rep2016112909227257458
   PubMedGoogle Scholar
• LiuPHHsuJWKungWCWuYCChangWYSuCMTumor lysis syndrome occurring after transarterial embolization in a 70-year-old man with a hepatocellular carcinoma ruptured in a motor vehicle accidentInt J Gerontol201482100102
   Google Scholar
• DharMPrakashSPandeyVPaiVKIntraoperative tumor lysis syndrome in a child with Wilms’ tumorAnesth Essays Res201610114514726957712
   PubMedGoogle Scholar
• DavidsonMBThakkarSHixJKBhandarkarNDWongASchreiberMJPathophysiology, clinical consequences, and treatment of tumor lysis syndromeAm J Med2004116854655415063817
   PubMed Web of Science ®Google Scholar
• Abu-AlfaAKYounesATumor lysis syndrome and acute kidney injury: evaluation, prevention, and managementAm J Kidney Dis2010555 Suppl 3S1S13
   PubMed Web of Science ®Google Scholar
• CairoMSBishopMTumour lysis syndrome: new therapeutic strategies and classificationBr J Haematol2004127131115384972
   PubMed Web of Science ®Google Scholar
• CairoMSCoiffierBReiterAYounesARecommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensusBr J Haematol2010149457858620331465
   PubMed Web of Science ®Google Scholar
• HowardSCJonesDPPuiCHThe tumor lysis syndromeN Engl J Med2011364191844185421561350
   PubMed Web of Science ®Google Scholar
• PfreundschuhMHow I treat elderly patients with diffuse large B-cell lymphomaBlood2010116245103511020805363
   PubMed Web of Science ®Google Scholar
• JonesGLWillAJacksonGHWebbNJARuleSBritish Committee for Standards in HaematologyGuidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in HaematologyBr J Haematol2015169566167125876990
   PubMed Web of Science ®Google Scholar
• EjazAAPourafsharNMohandasRSmallwoodBAJohnsonRJHsuJWUric acid and the prediction models of tumor lysis syndrome in AMLPLoS One2015103e011949725775138
   PubMed Web of Science ®Google Scholar
• SoodARBurryLDChengDKFClarifying the role of rasburicase in tumor lysis syndromePharmacotherapy200727111112117192165
   PubMed Web of Science ®Google Scholar
• SchumacherHRBeckerMALloydEMacDonaldPALademacherCFebuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety studyRheumatology (Oxford)200948218819419141576
   PubMed Web of Science ®Google Scholar
• BurnsCMWortmannRLNew drug class gout therapeutics: new drugs for an old diseaseLancet201137737716517720719377
   PubMedGoogle Scholar
• MayerMDKhosravanRVernilletLWuJ-TJoseph-RidgeNMulfordDJPharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairmentAm J Ther2005121223415662289
   PubMedGoogle Scholar
• SpinaMNagyZRiberaJMFLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS riskAnn Oncol201526102155216126216382
   PubMedGoogle Scholar
• TamuraKKawaiYKiguchiTEfficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy a phase III, randomized, multi-center trial comparing febuxostat and allopurinolInt J Clin Oncol2016215996100327017611
   PubMed Web of Science ®Google Scholar
• HochbergJCairoMSTumor lysis syndrome: current perspectiveHaematologica200893191318166779
   PubMedGoogle Scholar
• PatteCSakirogluOSommeletDEuropean experience in the treatment of hyperuricemiaSemin Hematol2001384 Suppl 10912
   PubMed Web of Science ®Google Scholar
• PatteCPhilipTRodaryCHigh survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 childrenJ Clin Oncol1991911231321985161
   PubMed Web of Science ®Google Scholar
• PuiCHRellingMVLascombesFUrate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignanciesLeukemia19971111181318169369411
   PubMed Web of Science ®Google Scholar
• PuiCHMahmoudHHWileyJMRecombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphomaJ Clin Oncol200119369770411157020
   PubMed Web of Science ®Google Scholar
• CortesJMooreJOMaziarzRTControl of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone – results of a multicenter phase III studyJ Clin Oncol201028274207421320713865
   PubMed Web of Science ®Google Scholar
• GoldmanSCHolcenbergJSFinklesteinJZA randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysisBlood2012971029983003
   Google Scholar
• CoiffierBMounierNBolognaSEfficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) studyJ Clin Oncol200321234402440614581437
   PubMed Web of Science ®Google Scholar
• JehaSKantarjianHIrwinDEfficacy and safety of rasburicase, a recombinant urate oxidase (Elitekt), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trialLeukemia200519343815510203
   PubMed Web of Science ®Google Scholar
• RényiIBárdiEUdvardiEPrevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin’s lymphomaPathol Oncol Res2007131576217387390
   PubMed Web of Science ®Google Scholar
• ShinHYKangHJParkESRecombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: results of a compassionate prospective multicenter study in KoreaPediatr Blood Cancer200646443944516123985
   PubMedGoogle Scholar
• KikuchiAKigasawaHTsurusawaMA study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndromeInt J Hematol200990449250019701676
   PubMed Web of Science ®Google Scholar
• PeaFPharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactionsContrib Nephrol2005147354615604604
   PubMed Web of Science ®Google Scholar
• UengSRasburicase (Elitek): a novel agent for tumor lysis syndromeProc (Bayl Univ Med Cent)200518327527916200184
   PubMedGoogle Scholar
• PuiCHRasburicase: a potent uricolytic agentExpert Opin Pharmacother20023443344211934348
   PubMedGoogle Scholar
• Vadhan-RajSFayadLEFanaleMAA randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndromeAnn Oncol20122361640164522015451
   PubMed Web of Science ®Google Scholar
• TrifilioSMPiJZookJEffectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignanciesBone Marrow Transplant201146680080520818444
   PubMed Web of Science ®Google Scholar
• CoutsouvelisJWisemanMHuiLEffectiveness of a single fixed dose of rasburicase 3mg in the management of tumour lysis syndromeBr J Clin Pharmacol201375255055322686734
   PubMed Web of Science ®Google Scholar
• CamparaMShordSSHaafCMSingle-dose rasburicase for tumour lysis syndrome in adults: weight-based approachJ Clin Pharm Ther200934220721319250141
   PubMed Web of Science ®Google Scholar
• HummelMBuchheidtDReiterSBergmannJHofheinzRHehlmannRSuccessful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndromeLeukemia200317122542254414523460
   PubMedGoogle Scholar
• KnoebelRWLoMCrankCWEvaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndromeJ Oncol Pharm Pract201117314715420332174
   PubMedGoogle Scholar
• LeeACLiCHSoKTChanRTreatment of impending tumor lysis with single-dose rasburicaseAnn Pharmacother200337111614161714565793
   PubMedGoogle Scholar
• ReevesDJBestulDJEvaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancerPharmacotherapy200828668569018503395
   PubMed Web of Science ®Google Scholar
• VinesANShanholtzCBThompsonJLFixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patientsAnn Pharmacother201044101529153720841516
   PubMed Web of Science ®Google Scholar
• PatelKSLauJEZembillasASGallagherEMSingle 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndromeJ Oncol Pharm Pract Epub4152016
   Google Scholar
• FengXDongKPhamDPenceSInciardiJBhutadaNSEfficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysisJ Clin Pharm Ther201338430130823550846
   PubMed Web of Science ®Google Scholar
• McBrideALathonSCBoehmerLAugustinKMButlerSKWesterveltPComparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndromePharmacotherapy201333329530323456733
   PubMed Web of Science ®Google Scholar
• AcostaAAHoggRJRasburicase for hyperuricemia in hemolytic uremic syndromePediatr Nephrol201227232532922089328
   PubMedGoogle Scholar
• CheukDKChiangAKChanGCHaSYUrate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancerCochrane Database Syst Rev201488CD006945
   Google Scholar
• EaddyMSealBTangiralaMDaviesEHO’DayKEconomic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patientsAm J Health Syst Pharm201067242110211421116002
   PubMed Web of Science ®Google Scholar
• DarmonMVincentFCamousLTumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-HématologiqueBr J Haematol2013162448949723772757
   PubMed Web of Science ®Google Scholar
• GalardyPJHochbergJPerkinsSLHarrisonLGoldmanSCairoMSRasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a children’s oncology group reportBr J Haematol2013163336537224032600
   PubMed Web of Science ®Google Scholar
• HochbergJCairoMSRasburicase: future directions in tumor lysis managementExpert Opin Biol Ther20088101595160418774926
   PubMed Web of Science ®Google Scholar
• AllenKCChamplainAHCotliarJARisk of anaphylaxis with repeated courses of rasburicase: a research on adverse drug events and reports (RADAR) projectDrug Saf201538218318725566825
   PubMed Web of Science ®Google Scholar
• MontgomeryKWBoothGSA perfect storm: tumor lysis syndrome with rasburicase-induced methemoglobinemia in a G6PD deficient adultJ Clin Apher Epub4272016
   PubMedGoogle Scholar
• NgJSEdwardsEMEgelundTAMethemoglobinemia induced by rasburicase in a pediatric patient: a case report and literature reviewJ Oncol Pharm Pract201218442543122190578
   PubMedGoogle Scholar
• BucklinMHGrothCMMortality following rasburicase-induced methemoglobinemiaAnn Pharmacother201347101353135824259700
   PubMedGoogle Scholar
• AlessaMACraigAKCunninghamJMRasburicase-induced meth-emoglobinemia in a patient with aggressive non-Hodgkin’s lymphomaAm J Case Rep20151659059326334783
   PubMedGoogle Scholar
• RobertsDAFreedJARasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problemEur J Haematol2015941838524750455
   PubMedGoogle Scholar
• NguyenAPNessGLHemolytic anemia following rasburicase administration: a review of published reportsJ Pediatr Pharmacol Ther201419431031625762877
   PubMedGoogle Scholar
• MiddekeJMBruckNParmentierSBornhauserMScheteligJUse of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndromeAnn Hematol201493353153223820942
   PubMed Web of Science ®Google Scholar
• OldfieldVPerryCMSpotlight on rasburicase in anticancer therapy-induced hyperuricemiaBioDrugs200620319719916724869
   PubMedGoogle Scholar
• AnnemansLMoeremansKLamotteMPan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patientsSupport Care Cancer200311424925712673464
   PubMed Web of Science ®Google Scholar
• EaddyMSealBTangiralaKDaviesEHO’DayKEconomic implications of rasburicase treatment in adult patients with tumour lysis syndromeAppl Health Econ Health Policy201210643144023013428
   PubMedGoogle Scholar